Informing mechanistic toxicology with computational molecular models.

Computational molecular models of chemicals interacting with biomolecular targets provides toxicologists a valuable, affordable, and sustainable source of in silico molecular level information that augments, enriches, and complements in vitro and in vivo efforts. From a molecular biophysical ansatz, we describe how 3D molecular modeling methods used to numerically evaluate the classical pair-wise potential at the chemical/biological interface can inform mechanism of action and the dose-response paradigm of modern toxicology. With an emphasis on molecular docking, 3D-QSAR and pharmacophore/toxicophore approaches, we demonstrate how these methods can be integrated with chemoinformatic and toxicogenomic efforts into a tiered computational toxicology workflow. We describe generalized protocols in which 3D computational molecular modeling is used to enhance our ability to predict and model the most relevant toxicokinetic, metabolic, and molecular toxicological endpoints, thereby accelerating the computational toxicology-driven basis of modern risk assessment while providing a starting point for rational sustainable molecular design.

[1]  S. Ekins,et al.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[2]  S. Wold,et al.  The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .

[3]  Ettore Novellino,et al.  A Critical Review of Recent CoMFA Applications , 1998 .

[4]  Sorel Muresan,et al.  ChemGPS-NP: tuned for navigation in biologically relevant chemical space. , 2006, Journal of natural products.

[5]  Michael M. Mysinger,et al.  Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[6]  S. Peterson Improved CoMFA Modeling by Optimization of Settings : Toward the Design of Inhibitors of the HCV NS3 Protease , 2007 .

[7]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[8]  Paul T Anastas,et al.  Toward a comprehensive molecular design framework for reduced hazard. , 2010, Chemical reviews.

[9]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[10]  T. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[11]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[12]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[13]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[14]  R. Campbell,et al.  Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). , 2008, Biochemical and biophysical research communications.

[15]  Melissa A. Pasquinelli,et al.  Computational Molecular Modeling for Evaluating the Toxicity of Environmental Chemicals: Prioritizing Bioassay Requirements , 2008, Environmental health perspectives.

[16]  Norman L. Allinger,et al.  Molecular mechanics. The MM3 force field for hydrocarbons. 1 , 1989 .

[17]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[18]  K. Maeda,et al.  Estimation of the Three-Dimensional Pharmacophore of Ligands for Rat Multidrug-Resistance–Associated Protein 2 Using Ligand-Based Drug Design Techniques , 2005, Pharmaceutical Research.

[19]  Gabriele Cruciani,et al.  Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach. , 2005, Journal of medicinal chemistry.

[20]  S. Ekins,et al.  Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. , 2002, Molecular pharmacology.

[21]  D. Dix,et al.  The ToxCast program for prioritizing toxicity testing of environmental chemicals. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  Jennifer L. Perry,et al.  Structure of the ochratoxin A binding site within human serum albumin , 2004 .

[23]  John J. Irwin,et al.  Community benchmarks for virtual screening , 2008, J. Comput. Aided Mol. Des..

[24]  David F. V. Lewis,et al.  Molecular modeling of human cytochrome P450–substrate interactions , 2002, Drug metabolism reviews.

[25]  Yongbo Hu,et al.  Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy , 2009, J. Chem. Inf. Model..

[26]  H A Scheraga,et al.  A comparison of the CHARMM, AMBER and ECEPP potentials for peptides. I. Conformational predictions for the tandemly repeated peptide (Asn-Ala-Asn-Pro)9. , 1989, Journal of biomolecular structure & dynamics.

[27]  Jin-Young Park,et al.  Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. , 2003, Journal of medicinal chemistry.

[28]  Ulf Norinder,et al.  3D‐QSAR investigation of the tripos benchmark steroids and some protein‐tyrosine kinase inhibitors of styrene type using the TDQ approach , 1996 .

[29]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[30]  Artem Cherkasov,et al.  Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening. , 2006, Journal of medicinal chemistry.

[31]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[32]  Olivier Sperandio,et al.  Free resources to assist structure-based virtual ligand screening experiments. , 2007, Current protein & peptide science.

[33]  Thierry Kogej,et al.  ChemGPS-NPWeb: chemical space navigation online , 2009, J. Comput. Aided Mol. Des..

[34]  Hugo Kubinyi,et al.  From Narcosis to Hyperspace: The History of QSAR , 2002 .

[35]  Roland L Dunbrack,et al.  Outcome of a workshop on applications of protein models in biomedical research. , 2009, Structure.

[36]  C. Wermuth,et al.  Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) , 1998 .

[37]  Michael-Rock Goldsmith,et al.  Molecular modeling for screening environmental chemicals for estrogenicity: use of the toxicant-target approach. , 2009, Chemical research in toxicology.

[38]  Tudor I. Oprea,et al.  Chemical database preparation for compound acquisition or virtual screening. , 2006, Methods in molecular biology.

[39]  Ulf Norinder,et al.  Recent Progress in CoMFA Methodology and Related Techniques , 1998 .

[40]  Michael M. Mysinger,et al.  Automated Docking Screens: A Feasibility Study , 2009, Journal of medicinal chemistry.

[41]  A. Leo,et al.  Partition coefficients and their uses , 1971 .

[42]  T. Cheatham,et al.  Molecular dynamics simulation of nucleic acids: Successes, limitations, and promise * , 2000, Biopolymers.

[43]  I. Rusyn,et al.  Computational Toxicology: Realizing the Promise of the Toxicity Testing in the 21st Century , 2010, Environmental health perspectives.

[44]  G. W. Price,et al.  Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. , 2003, Molecular pharmacology.

[45]  M. Hartmann Molecular mechanics. Von ULRICH BURKERT und NORMAN L. ALLINGER. ACS Monograph 177. Washington: American Chemical Society 1982. 430 S., US $ 77.95 , 1984 .

[46]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[47]  F. Ban,et al.  In silico identification of anthropogenic chemicals as ligands of zebrafish sex hormone binding globulin. , 2009, Toxicology and applied pharmacology.

[48]  Lynda B. M. Ellis,et al.  The University of Minnesota Biocatalysis/Biodegradation Database: post-genomic data mining , 2003, Nucleic Acids Res..

[49]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[50]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[51]  J. Ponder,et al.  Force fields for protein simulations. , 2003, Advances in protein chemistry.

[52]  Y. Kurogi,et al.  Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. , 2001, Current medicinal chemistry.

[53]  H. Scheraga,et al.  A comparison of the CHARMM, AMBER and ECEPP potentials for peptides. II. Phi-psi maps for N-acetyl alanine N'-methyl amide: comparisons, contrasts and simple experimental tests. , 1989, Journal of biomolecular structure & dynamics.

[54]  Lester A. Mitscher,et al.  Glossary of terms used in medicinal chemistry , 1998 .

[55]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.

[56]  Sean Ekins,et al.  A pharmacophore for human pregnane X receptor ligands. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[57]  K. Gundertofte,et al.  A comparison of conformational energies calculated by several molecular mechanics methods , 1996 .